

IN THE NAME OF GOD

Seizure

SADRZADEH MD.

ASSISTANT PROF. OF EM MEDICINE

- The majority of seizures will cease spontaneously **within 5 minutes**
- **Status Epilepticus**
- Prompt identification and, whenever possible, reversal of seizure **triggers** are priorities. In particular, assessing for and correcting hypoglycemia should occur as early as possible.

Initial care

- Assess airway, breathing, and circulation
- Pulse oximetry
- Electrocardiogram
- Finger stick (give IV dextrose if glucose <60 mg/dL)
- Aspiration precautions (lateral decubitus)

PULSE check / Bedside Protection

lateral decubitus positioning and suctioning of oral cavity are important to prevent aspiration

First-line therapy:

- Diazepam 5 mg up to a max of 20 mg
- Lorazepam 2–4mg up to max of 10 mg
- Midazolam 5–10 mg IV/IM/intranasal

the use of intraoral devices may lead to trauma without additional benefit


Yes

Did the seizure stop?

No


TABLE 14.2 Commonly Used Parenteral Antiseizure Agents, Dosing, and Pharmacologic Considerations for Status Epilepticus

Medication	Adult Dose	Comments
First Line		
Diazepam	0.15–0.2 mg/kg IV over 1–2 min <u>max 10 mg per dose,</u> 10–20 mg PR	Repeat doses <u>every 5 min to a maximum of 30 mg;</u> <u>monitor respiratory status.</u> Rapid redistribution. IV formulation contains propylene glycol. Preferred benzodiazepine for rectal route when IM midazolam and IV lorazepam are not available
Lorazepam	0.1 mg/kg IV over 1–2 min (<u>maximum 4 mg per dose</u>)	Repeat doses <u>every 5 min to a maximum of 12 mg (adults);</u> <u>monitor respiratory status.</u> Rapid redistribution. IV formulation contains propylene glycol. Preferred IV benzodiazepine; do NOT administer IM.
Midazolam	0.2 mg/kg IV over 1–2 min, IM, IN (<u>max of 10 mg per dose</u>)	Repeat doses <u>may be administered every 5 min;</u> <u>monitor respiratory status.</u> Half-life ~7 h. Rapid redistribution. Active metabolites. <u>Preferred IM benzodiazepine.</u>



Second Line

Levetiracetam	<u>1000–4500 mg over 10–15 mins (40-60 mg/kg for status epilepticus; maximum of 4500 mg)</u>	Renally cleared.
Fosphenytoin	10–20 mg PE/kg IV (max 150 mg PE/min), IM	May give an additional 5 PE/kg 10 min after loading dose. May cause hypotension and dysrhythmia but less profound than phenytoin. May be administered IM if no IV access. Compatible in saline, dextrose and lactated Ringers.
Lacosamide	200–400 mg IV over 10 min	May give an additional 5 mg/kg over 5 min (max 250 mg IV). May cause arrhythmias (prolonged PR and QTc intervals, or tachyarrhythmias). Renally cleared.
Phenobarbital	<u>15–20 mg/kg at 50–100 mg/min</u>	May give additional 5–10 mg /kg. Monitor respiratory status. Strong cytochrome P450 (CYP) inducer. IV formulation contains propylene glycol.
Phenytoin	<u>15–20 mg/kg IV infusion maximum at 50 mg/min (25 mg/min in patients with cardiac history)</u>	May give an <u>additional 5–10 mg/kg</u> 10 min after the load, <u>up to 30 mg/kg total</u> . May cause <u>hypotension and dysrhythmia</u> . Potent CYP inducer. May cause rash, fever. IV formulation contain propylene glycol. Only <u>compatible in saline</u> . Severe tissue injury risk with <u>extravasation</u> .
Valproic acid	<u>20–40 mg/kg IV over 5–10 min; max 3000 mg.</u>	May give <u>additional 20 mg/kg (max 2000 mg) over 5 min</u> . Potent CYP inhibitor. May cause <u>hyperammonemia, hepatotoxicity, and platelet dysfunction</u> .



Third Line—Require Intubation, Mechanical Ventilation, and Hemodynamic Support

<u>Ketamine</u>	Loading: <u>1.5 mg/kg IV over 3–5 min</u> May repeat 0.5 mg/kg every 3–5 mins as needed Maintenance: starting dose 0.1–4 mg/kg/hr, max 15 mg/kg/hr	NMDA antagonist, which provides an alternative treatment to GABAergic mediated anesthetics. <u>May cause hypotension when shock index ≥ 0.9.</u> Higher infusion rates associated with large volumes due to dilution.
<u>Midazolam</u>	Loading: 0.2 mg/kg IV, followed by 0.2 mg/kg every 3–5 min (max 2 mg/kg) May repeat 0.2–0.4 mg/kg (max 40 mg bolus) max 2 mg/kg Maintenance: 0.05–2 mg/kg/h	May cause hypotension with higher doses.
<u>Pentobarbital</u>	Loading: 5–15 mg/kg at 50 mg/min, may administer an additional 5–10 mg/kg if needed, max 25 mg/kg Maintenance: 0.5–5 mg/kg/h	Half-life 22 h (up to 50 h as it is dose dependent). May cause hypotension, ileus, myocardial suppression, immunosuppression, and thrombocytopenia. Contains propylene glycol.
<u>Propofol infusion</u>	Loading: <u>1–2 mg/kg</u> , may repeat 0.5–2 mg/kg every 3–5 mins up to max of 10 mg/kg total Maintenance: normal range 20–80 mcg/kg/min, max 200 mcg/kg/min	Half-life 0.6 h (extended with prolonged infusions). May cause hypotension, respiratory depression, hypertriglyceridemia, pancreatitis, propofol infusion syndrome

Lab Tests

- **BS glucometry / Serum BS**
- **Sodium, Calcium, and Magnesium** levels
- **CPK** : (seizure > 2 minutes)
- **A Pregnancy test**
- **Toxicology screen**
- **ABG** : Anion gap metabolic acidosis is commonly secondary to **lactic acidosis** in convulsive seizures; acidosis is typically **transient** with lactic acid levels declining within the first hour after convulsions cease

Lab Tests

- Patients with or without history of epilepsy who are on **Antiseizure Medications** for any indication (i.e., seizure prophylaxis, mood stabilization, anxiety, and/or adjunctive psychiatric treatment) should have **levels obtained**, as available
- **Reactive leukocytosis** of varying magnitude is very common after convulsive seizures
- **Lumbar puncture**

BOX 14.1 Characteristics Prompting Consideration of Neuroimaging in a Patient With Seizures

Age >40 years

Coma

Immunocompromised state

Clot disorder (hypercoagulability or hypocoagulability)

History of intracranial hemorrhage

History of malignancy

Severe, thunderclap headache

Status epilepticus, convulsive and nonconvulsive, of unclear etiology

Stigmata of neurocutaneous syndromes

Suspected trauma

THANK YOU